# Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)

> **NCT01449071** · PHASE1,PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 20 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Epratuzumab 400 mg
- **BIOLOGICAL:** Epratuzumab 1200 mg
- **BIOLOGICAL:** Epratuzumab 100 mg
- **BIOLOGICAL:** Epratuzumab 600 mg

## Key facts

- **NCT ID:** NCT01449071
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01449071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01449071, "Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01449071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*